Physician profile
Mark Urman
NPI 1497827448
$1,038.34
in general payments reported to CMS, 2019-2025
12 companies · $604 in 2025
The $604 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $0.83 · 2022: $19.90 · 2023: $49.12 · 2024: $365 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $419.21 | 2022-2025 | |
| Pfizer INC. | $182.67 | 2023-2025 | |
| Heartflow, INC. | $136.10 | 2024-2025 | |
| Irhythm Technologies, INC. | $73.60 | 2024 | Zio Xt Patch, Zio Monitor |
| E.R. Squibb & Sons, L.L.C. | $71.77 | 2024-2025 | Eliquis, Camzyos |
| Amgen INC. | $34.42 | 2025 | Repatha |
| Esperion Therapeutics, INC. | $24.83 | 2024 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $24.12 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $24.04 | 2025 | |
| Baxter Healthcare | $23.95 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $22.80 | 2024 | Rybelsus, Ozempic |
| Travere Therapeutics, INC. | $0.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Urman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.